Clinical Trials on Breastfeeding Duration

Total 2106 results

Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Aga Khan University Hospital, Pakistan

Completed

Frequency of Occult Breast Cancer After Prophylactic Mastectomy Among High-Penetrance Breast Cancer Gene Positives (OBC-PM)

Breast Cancer | Genetic Predisposition | BRCA Mutation | Occult Cancer

Pakistan
Necmettin Erbakan University

Completed

The Effect of Propolis in Tinea Pedis Treatment: A Randomized Controlled Study

Nurse's Role | Patient Education | Foot Care

Turkey
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

France
Novartis Pharmaceuticals

No longer available

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy (AMLFLT3)

Acute Myeloid Leukemia (AML) With | FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

Obesity | Overweight | Ductal Breast Carcinoma In Situ | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Premalignant Lesion

United States
Brown University
Pfizer; Lifespan

Terminated

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Stage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
University of Miami
Endo Pharmaceuticals

Recruiting

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

Sexual Dysfunctions, Psychological | Genital Diseases, Male | Peyronie Disease

United States
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
Hunan Province Tumor Hospital

Recruiting

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Carcinoma, Non-Small Cell Lung | EGFR Gene Mutation

China
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Abramson Cancer Center at Penn Medicine
Pfizer

Active, not recruiting

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | KRAS Mutation-Related Tumors

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluating the Collaborative Management in Pediatrics (CMP) Training Program Among Pediatric Resident Doctors and Their Patients With Asthma or Obesity (CMP)

Obesity | Asthma | Education

United States
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Stanford University

Not yet recruiting

Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations

PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome | PTEN Hamartoma Syndrome

United States
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Masaryk University
Brno University Hospital; Roche s.r.o.

Recruiting

Pediatric Prospective Personalized Immune and Target Identification Trial (PPROSPERITIT)

Central Nervous System Neoplasms | Pediatric Cancer | Tumor, Brain | GEN1 Gene Mutation

Czechia
Haihe Biopharma Co., Ltd.

Recruiting

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

C-Met Exon 14 Mutation

China, Japan, United States
David E Gerber
Cancer Prevention Research Institute of Texas; Sagimet Biosciences Inc.

Recruiting

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

KRAS Gene Mutation

United States
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
Chul Kim
Bristol-Myers Squibb; AstraZeneca; Walter Reed National Military Medical Center; Hackensack Meridian Health

Active, not recruiting

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Nonsmall Cell Lung Cancer | EGFR Gene Mutation

United States
Korean Association for the Study of Targeted Therapy
Chonnam National University Hospital; Kyungpook National University Hospital; Konkuk University Medical Center and other collaborators

Completed

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

HER2 Gene Mutation | Adenocarcinoma Lung Stage IV

Korea, Republic of
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Not yet recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER)

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
Clinical Nutrition Research Center, Illinois Institute...
Hass Avocado Board; National Mango Board

Active, not recruiting

Dietary Exchanges With Avocado and Mango in Pre-diabetes (AVMa)

Cognitive Change | Vascular Stiffness | Pre Diabetes | Retinal Vascular | Vascular Dilation

United States
The Fourth Affiliated Hospital of Zhejiang University...

Completed

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

NSCLC | EGFR Gene Mutation | Non-small-lung-cell Cancer

China
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...
University of Campania "Luigi Vanvitelli"; IRCCS National Neurological Institute...

Active, not recruiting

Ambroxol as a Disease-modifying Treatment in GBA-PD (AMBITIOUS)

Parkinson Disease | GBA Gene Mutation

Italy
University of California, San Francisco
Oregon Health and Science University

Completed

Deceased Organ Donor Interventions to Protect Kidney Graft Function

Brain Death | Organ Donation | Delayed Graft Function | Organ Transplant Failure or Rejection

United States
Ankara University

Completed

The Effect of Education Provided to Family Members Caring for Colorectal Cancer Patients on Caregiving Reactions and Healthy Lifestyle Behaviors: A Prospective Quasi-experimental Study.

Evaluation of the Effects of Education Provided on Family Members Caring for Colorectal Cancer Patients

Turkey
Shanghai Chest Hospital

Completed

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Lung Adenocarcinoma | EGFR Activating Mutation
The University of Hong Kong

Unknown

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB

Hong Kong
Amsterdam UMC, location VUmc

Unknown

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

NSCLC | EGFR-mutation | HER2-expression

Netherlands
Murdoch Childrens Research Institute
Royal Children's Hospital; Peter MacCallum Cancer Centre, Australia

Not yet recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Arteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditions

Australia
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
Memorial Sloan Kettering Cancer Center

Completed

Continued Access to RXDX-105

Ovarian Cancer | Non Small Cell Lung Cancer | RET Gene Mutation | BRAF Gene Mutation

United States
Ohio State University Comprehensive Cancer Center

Completed

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
University of Washington
National Cancer Institute (NCI); National Institute of Nursing Research (NINR)

Completed

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer (DEEM)

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ | Atypical Lobular Breast Hyperplasia

United States
University of Southern California
National Cancer Institute (NCI); California Breast Cancer Research Program

Completed

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Lobular Breast Carcinoma in Situ

United States
Centre Oscar Lambret
CTD-CNO; Laboratoire PRISM

Active, not recruiting

Radical Fimbriectomy for Young BRCA Mutation Carriers (Fimbriectomy)

BRCA1 Mutation | BRCA2 Mutation | Hereditary Breast and Ovarian Cancer

France
Centre Hospitalier Universitaire Dijon

Completed

Research Into the Molecular Bases of a New Phenotype Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia (BCL-2)

New Phenotype (Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia)

France
Suzhou Genhouse Bio Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

China
Qianqian Qu

Not yet recruiting

DKI Combined With APT for Post-treatment Assessment of Ovarian Malignancies and Correlation With XRCC2 Gene

Malignant Tumor of the Ovary | XRCC2 Gene Mutation
University Hospital, Clermont-Ferrand
Diagnostica Stago

Recruiting

Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System (EVIGE)

Patients Without a Medical History of Thrombosis or Hemorrhage | Hemophilic Patient | Patient With FV Leiden Mutation | Patient With Cirrhosis | Patient on Anticoagulant

France
The Foundation for Orthopaedics and Regenerative...

Recruiting

Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis

Erectile Dysfunction | Interstitial Cystitis | Peyronie's Disease

Antigua and Barbuda
Novartis Pharmaceuticals

Completed

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

BRAF V600 Mutation Positive Melanoma

China
National Taiwan University Hospital

Completed

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Tumor Progression | EGFR Exon 19 Mutation

Taiwan
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Qingdao Central Hospital

Completed

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

EGFR-TKI Resistant Mutation

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer | EGFR Gene Mutation

China

Clinical Trials on Breastfeeding Duration

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations